Dear COVID-19 Vaccination Provider:

On September 24, 2021, under the U.S. Food and Drug Administration’s (FDA) updated emergency use authorization (EUA), the CDC issued recommendations for a single dose of the Pfizer-BioNTech COVID-19 Vaccine at least six months after completion of the primary series for the following individuals:

  • individuals 65 years of age and older, and residents in long-term care settings
  • individuals 50-64 years of age with underlying medical conditions
  • individuals 18-49 years of age with underlying medical conditions, based on individual benefit and risks.
    (This can be based on shared clinical decision-making and encourages, but does not require, prior consultation with a provider before administration of a booster dose.)
  • individuals 18-64 years of age who are at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting, based on their individual benefits and risks.

Due to insufficient data at this time, the EUA amendment for a booster dose does not apply to the Moderna COVID-19 vaccine or the Janssen/Johnson & Johnson COVID-19 vaccine, and does not support the use of a Pfizer-BioNTech COVID-19 vaccine dose after two doses of the Moderna COVID-19 vaccination or the single-dose Janssen/Johnson & Johnson COVID-19 vaccination.

All providers enrolled in the NYS COVID-19 vaccination program are authorized to expand eligibility for these individuals to receive booster doses, effective immediately.

Please see the attached program guidance for important operational details including specific eligibility.

Screening Checklist for the COVID-19 Vaccine

Thank you for your participation in the COVID-19 Vaccination Program.

The NYS COVID-19 Vaccine Team

Categories: Covid ResourcesPublished On: September 27th, 2021Tags: , , ,


Related Posts

  • FDA Authorizes Updated (Bivalent) COVID-19 Vaccines for Children Down to 6 Months of Age – December 9, 2022   Dear COVID-19 Vaccination Provider: On December 8, 2022, FDA authorized the bivalent Moderna COVID-19 vaccine for children ages 6 months through 5 years of age and bivalent Pfizer-BioNTech COVID-19 vaccine for children 6 months through 4 […]

  • Yesterday, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna COVID-19 Vaccine, Bivalent and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent to authorize their use as a single booster dose in younger age groups: CDC’s Director Dr. Rochelle Walensky released a statement and signed a decision memo recommending updated (bivalent) COVID-19 boosters for children five years and older. This expands on CDC's recommendation issued September 1, 2022, for updated COVID-19 boosters of people ages 12 and older.

  • Updated Clinical Guidance For Individuals 6 Months-11 Years Old – June 22, 2022   Dear NYS COVID-19 Vaccine Provider: Effective June 18, 2022, the CDC has recommended that everyone ages 6 months and older in the United States should receive a COVID-19 primary series vaccination for the prevention of COVID-19. This attached provider guidance has […]

  • Updated Guidance for The New York State COVID-19 Vaccination Program for Individuals 12 Years of Age or Older June 13, 2022   Note: This guidance document applies specifically to health care providers offering COVID-19 vaccinations to adolescents and adults ages 12 and older. Guidance specific to COVID-19 vaccination of children ages 5-11 can be found […]